Last reviewed · How we verify
Topical calcipotriol
Calcipotriol is a vitamin D3 analog that binds to vitamin D receptors on skin cells to regulate cell proliferation and differentiation, reducing excessive skin cell growth.
Calcipotriol is a vitamin D3 analog that binds to vitamin D receptors on skin cells to regulate cell proliferation and differentiation, reducing excessive skin cell growth. Used for Psoriasis (topical treatment), Atopic dermatitis (topical treatment).
At a glance
| Generic name | Topical calcipotriol |
|---|---|
| Sponsor | Post Graduate Institute of Medical Education and Research, Chandigarh |
| Drug class | Vitamin D3 analog |
| Target | Vitamin D receptor (VDR) |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
Calcipotriol activates the vitamin D receptor (VDR) on keratinocytes and immune cells in the skin, promoting normal cell maturation and reducing the abnormal proliferation characteristic of psoriasis. This leads to normalization of the epidermal differentiation process and anti-inflammatory effects through modulation of immune cell function.
Approved indications
- Psoriasis (topical treatment)
- Atopic dermatitis (topical treatment)
Common side effects
- Skin irritation
- Burning sensation
- Pruritus
- Erythema
Key clinical trials
- Comparison of Topical Photodynamic Therapy With Topical Calcipotriol in Management of Oral Leukoplakia (PHASE3)
- Comparison of Topical Calcipotriol and Intralesional Steroids in Alopecia Areata (PHASE4)
- Effects of Semaglutide on Clinical Outcomes and Metabolic Inflammation in Psoriasis (PHASE4)
- Topical 5-Fluorouracil (5FU) Plus Calcipotriol in Children With Palmoplantar Wart (NA)
- A Pilot Clinical Trial Comparing Topical Fluorouracil to Fluorouracil Plus Calcipotriene Field Treatments in Patients With Multiple Actinic Keratoses (PHASE3)
- Residual Disease MEMory in PSOriasis Skin During EnstiLAR® and Narrow-band Ultraviolet B Therapy: The MEMPSOLAR Study (PHASE4)
- Testing the Efficacy of Topical Calcipotriene Plus 5-Fluorouracil Combination to Activate the Immune System Against Precancerous Skin Lesions in Organ Transplant Recipients (PHASE2)
- COMPARISON OF EFFICACY AND SAFETY OF NARROWBAND UVB WITH 0.1% TACROLIMUS VS NARROWBAND UVB WITH 0.005% CALCIPOTRIOL IN TREATMENT OF VITILIGO (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: